BRCA检验的全球市场 - 市场规模(各市场区隔)，占有率，法规，偿付，预测(～2033年)

本报告提供全球BRCA检验市场相关调查分析，提供主要企业与市场占有率，主要趋势，创新的产品与技术，竞争情形等资讯。

市场模型的主要内容如下。

已上市的 BRCA 测试和不断变化的竞争格局

• 对主要产业趋势的考虑
• BRCA 测试市场年收入与市场前景（按细分市场）（2015-2033 年）
• 有关单位数量、平均售价和市场价值的市场级数据

全球、区域和国家层面的特定市场考量

• 按地区细分全球趋势的特定市场定性资讯和国家/地区考虑因素
• BRCA检测市场的SWOT分析
• BRCA 检测市场竞争动态的考量与趋势

透过对医疗保健系统的真实、全面的了解来促进市场了解。市场进入部分还提供有关报销政策和监管环境的信息，使您能够更深入地研究市场动态。

• 各国医疗保健系统概览
• 按国家/地区划分的报销政策
• 各国医疗科技监理状况

对象企业

• NGeneBio Co Ltd
• Agilent Technologies Inc
• Illumina Inc
• NimaGen BV
• Qiagen NV
• Takara Bio Inc
• New England Biolabs Inc
• Amoy Diagnostics Co Ltd
• MRC-Holland BV
• 其他

BRCA Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.

Breast cancer type 1 (BRCA1) and Breast cancer type 1 (BRCA1 gene tests, under the overall umbrella of BRCA Tests, are carried out to detect gene rearrangements within blood samples; the outcome of which may guide therapies and prophylactic actions to treat or prevent certain types of breast and ovarian cancer.

Breast cancer is generally subdivided into different categories, depending on expression levels of cellular receptors for estrogen (ER), progesterone (PgR), and human epidermal growth factor receptor 2 (HER2). Since aberrant activity contributes to tumour genesis, molecular-targeted therapies exist for breast cancer patients that express one or more of these three receptors.

Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed BRCA tests and evolving competitive landscape -

• Insightful review of the key industry trends.
• Annualized total BRCA tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights -

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for BRCA Tests market.
• Competitive dynamics insights and trends provided for BRCA Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: NGeneBio Co Ltd, Agilent Technologies Inc, Illumina Inc, NimaGen BV, Qiagen NV, Takara Bio Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, MRC-Holland BV, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the BRCA Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products, by identifying key companies.
• Develop business strategies by understanding the trends shaping and driving BRCA tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BRCA tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific BRCA tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.